Interactions Between Technetium-99m Radiopharmaceuticals and Plasma Proteins: A Molecular Docking Study

  • V. Trusova Department of Medical Physics and Biomedical Nanotechnologies, V.N. Karazin Kharkiv National University, Kharkiv, Ukraine https://orcid.org/0000-0002-7087-071X
  • P. Kuznietsov O.I. Akhiezer Department for Nuclear Physics and High Energy Physics, V.N. Karazin Kharkiv National University, Kharkiv, Ukraine https://orcid.org/0000-0001-8477-1395
  • I. Yakymenko O.I. Akhiezer Department for Nuclear Physics and High Energy Physics, V.N. Karazin Kharkiv National University, Kharkiv, Ukraine https://orcid.org/0000-0002-0194-8376
  • G. Gorbenko Department of Medical Physics and Biomedical Nanotechnologies, V.N. Karazin Kharkiv National University, Kharkiv, Ukraine https://orcid.org/0000-0002-0954-5053
DOI: https://doi.org/10.26565/2312-4334-2026-3-61
Keywords: Technetium-based radiotracers, Transthyretin, Fibrinogen, Alpha1-acid glycoprotein, Immunoglobulin G, Molecular docking

Abstract

Technetium-99m (99mTc) is the most widespread radionuclide with physicochemical characteristics highly suitable for diagnostic nuclear medicine. The radiopharmaceuticals obtained by complexation of 99mTc with ligating agents or targeting biomolecules are increasingly used for diagnostic purposes in oncology, cardiology, nephrology, neurology and other fields of medical practice. One factor that may influence clinical efficiency of 99mTc radiotracers involves their interactions with the proteins of human blood plasma. Most studies of such kind of interactions have been focused on albumin, while much less attention was given to other protein components of blood plasma. In the present work the molecular docking technique was employed to evaluate the possibility of association between a series of 99mTc radiopharmaceuticals and plasma proteins including transthyretin, fibrinogen, alpha1-acid glycoprotein, Fc and Fab fragments of immunoglobulin G. It was found that the investigated 99mTc compounds (except pertechnetate) form the strongest complexes with alpha1-acid glycoprotein and fibrinogen. The affinities of TcMED, TcDTPA, TcMAG, TcECD, TcDIS and TcMEB for alpha1-acid glycoprotein and fibrinogen appeared to be higher than those for albumin. The structural characteristics of both plasma proteins and 99mTc radiotracers were demonstrated to determine the amino acid composition of the binding sites. The presence of peptide fragments in the structure of 99mTc compounds was assumed to markedly increase their affinity for plasma proteins. The results obtained may be helpful for gaining deeper insights into biodistribution pattern of 99mTc radiopharmaceuticals.

Downloads

Download data is not yet available.

References

M.U. Akbar, M.R. Ahmad, A. Shaheen, and S. Mushtaq, J. Radioanal. Nucl. Chem. 310, 477–493 (2016). https://doi.org/10.1007/s10967-016-5019-7

T. J. Ruth, Annu. Rev. Nucl. Part. Sci. 70, 77–94 (2020). https://doi.org/10.1146/annurev-nucl-032020-021829

M. T. Ma, Front. Chem. Biol. 4, 1729615 (2026). https://doi.org/10.3389/fchbi.2025.1729615

G. M. Currie, and E. M. Rohren, Semin. Nucl. Med. 55, 829-840 (2025). https://doi.org/10.1053/j.semnuclmed.2025.01.005

E. Strub, D. Badea, J. Bruns, A. Frontera, N. Mayordomo, A. Sakhonenkova, M. R. Jungfer, M. Wickleder, C.Yong, and M. Zegke, Eur. J. Inorg. Chem. 28, e202400780 (2025). https://doi.org/10.1002/ejic.202400780

N. Ahmed, and M. Zia, J. Acad. Radiol. 6, 143–159 (2023). https://doi.org/10.1007/s42058-023-00128-7

A. Maruk, A. Bruskin, and G. Kodina, Radiochemistry 53, 341–353 (2011). https://doi.org/10.1134/S1066362211040011

I. Ibrahim, J. Radioanal. Nucl. Chem, 281, 669–674 (2009). https://doi.org/10.1007/s10967-009-0040-8

M. Sanad, Radiochemistry 55, 539–544 (2013). https://doi.org/10.1134/S1066362213050159

E. von Guggenberg, H. Dietrich, I. Skvortsova, M. Gabriel, I. Virgolini, and C. Decristoforo, Eur. J. Nucl. Med. Mol. Imaging 34, 1209–1218 (2007). https://doi.org/10.1007/s00259-006-0348-3

Y. Arano, Ann. Nucl. Med. 16, 79–93 (2002). https://doi.org/10.1007/BF02993710

A. S. Dzik-Jurasz, Br. J. Radiol. 76, 98–109 (2003). https://doi.org/10.1259/bjr/25833499

V. Trusova, U. Malovytsia, P. Kuznietsov, I. Yakymenko, and G. Gorbenko, East Eur. J. Phys. 2, 405-411 (2025). https://doi.org/10.26565/2312-4334-2025-2-49

M. A. Liz, T. Coelho, V. Bellotti M. I. Fernandez-Arias, P. Mallaina, and L. Obici, Neurol. Ther. 9, 395–402 (2020). https://doi.org/10.1007/s40120-020-00217-0

A. S. Wolberg, J. Thromb. Haemost. 21, 3005-3015 (2023). https://doi.org/10.1016/j.jtha.2023.08.014

T. Fournier, N. Medjoubi, and D. Porquet, Biochim. Biophys. Acta Protein Struct. Mol. Enzymol. 1482, 157–171 (2000). https://doi.org/10.1016/S0167-4838(00)00153-9

S. Yanaka, R. Yogo,and K. Kato, Biophys. Rev. 12, 637–645 (2020). https://doi.org/10.1007/s12551-020-00698-1

S. Rathmann, Z. Ahmad, S. Slikboer, H. Bilton, D. Snider, and J. Valliant, In: J. Lewis, A. Windhorst, B. Zeglis (eds) Radiopharmaceutical Chemistry. Springer, Cham. (2019). https://doi.org/10.1007/978-3-319-98947-1_18

Y. Yan, H. Tao, J. He, and S-Y. Huang, Nat. Protoc. 15, 1829–1852 (2020). https://doi.org/10.1038/s41596-020-0312-x

V. Trusova, P. Kuznietsov, I. Yakymenko, and G. Gorbenko, East Eur. J. Phys. 1, 520-524 (2026). https://doi.org/10.26565/2312-4334-2026-1-59

Published
2026-09-07
Cited
How to Cite
Trusova, V., Kuznietsov, P., Yakymenko, I., & Gorbenko, G. (2026). Interactions Between Technetium-99m Radiopharmaceuticals and Plasma Proteins: A Molecular Docking Study. East European Journal of Physics, (3), 654-658. https://doi.org/10.26565/2312-4334-2026-3-61
Issue
No. 3 (2026): East European Journal of Physics
Section
Original Papers

Copyright (c) 2026 V. Trusova, P. Kuznietsov, I. Yakymenko, G. Gorbenko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
    • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
    • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).